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Introduction
The combination of lifestyle and human behavioral changes, such as sedentary daily routine, excessive caloric intake and obesity, have resulted in the global epidemic of chronic illnesses such as hypertension, diabetes mellitus and chronic kidney disease (CKD) [1] [2] [3] . Diabetes is the most common cause of end-stage kidney disease in the developed world. It is expected that as the number of people with Type 2 diabetes doubles in the next 25 years, a rise in the global burden of CKD will also be observed. Cancer, an important and prevalent problem in the general population, has been shown to occur more commonly in people with diabetes [4, 5] . Type 2 diabetes has been reported to confer a 2-fold increased risk of endometrial and liver cancer, a 3-fold increase in pancreatic cancers [6, 7] and at least a 1.5-fold increased risk of colorectal, breast and bladder cancers [8] [9] [10] . Type 2 diabetes has also been shown to be associated with an increased risk of site-specific cancer mortality among Asians and nonAsians, but improved glucose control in these populations did not alter the underlying increased cancer risk [11, 12] .
Cancer is a well-established and recognized complication for people with CKD requiring renal replacement therapy such as kidney transplantation and dialysis [13] . An overall increased risk of cancer in those with mild to moderately reduced kidney function has also recently been described by two other population-based observational studies. The increased cancer risk observed after transplantation may be attributed to the effects of longterm immunosuppression. However, the biological rationale for the increased risk of malignancy in those with early to moderate CKD is unclear [14, 15] .
Given that diabetes and CKD are both independently associated with an increased risk of cancer, it is reasonable to hypothesize that the combined effects of diabetes and CKD would further augment an individual's overall risk of cancer. Using data from the Action in Diabetes and Vascular disease: Preterax and Diamicron MR controlled evaluation (ADVANCE) trial, we aimed to determine the association of moderately reduced kidney function and the overall and site-specific risk of incident cancers among people with Type 2 diabetes mellitus.
Materials and methods

Study population
The ADVANCE trial was an investigator-initiated, multicenter, two-bytwo factorial randomized controlled trial of blood pressure lowering and glucose control in people with Type 2 diabetes. Participants were randomly allocated to a fixed combination of perindopril and indapamide or matching placebo, and an intensive gliclazide-modified release-based glucose control regimen (aiming at HbA1c ≤ 6.5%) or standard blood glucose control. They were followed up over a median duration of 5 years. Full details of the recruitment process have been published elsewhere [16, 17] . In brief, participants aged ≥55 years were required to have either a history of macro-or microvascular disease, or at least one risk factor for vascular disease, at the time of study entry. Patients on renal replacement therapy (on dialysis or with kidney transplants) or those who had active and untreated malignant neoplasms were excluded from the study.
Baseline characteristics of the study cohort Baseline data were collected on self-reported medical and treatment history and the associated major risk factors such as smoking status and history of alcohol intake using a standard protocol. Height and weight were measured without shoes and without outdoor or heavy clothing. Body mass index (BMI) was defined as weight (kg)/height (m 2 ). Systolic and diastolic blood pressures were recorded as the mean of two measurements made in the seated position using an automated sphygmomanometer (Omron HEM-705 CP; Omron, Kyoto, Japan). Cognitive function was assessed using the standard Mini-Mental State Examination (MMSE). Laboratory measurements were collected at a local laboratory using standard protocols. Participating laboratories in the ADVANCE trial underwent a standardization process using the Wales External Quality Assurance Scheme (WEQAS) [16] .
We defined participants as having moderate CKD, with an estimated glomerular filtration rate (eGFR) of < 60 mL/min/1.73 m 2 , calculated using the Modification of Diet in Renal Disease (MDRD) equation.
Assessment of incident cancers
Incident cancers were defined as the first cancer diagnosed after entry to the study (between June 2001 and March, 2003). Diagnoses of incident cancers were coded using the International Classification of Diseases Code Tenth Revision (ICD-10) for neoplasms (C00-D48); malignant neoplasm (C00-C97); malignant neoplasm except lymphoid tissue (C0-C75); lip, oral cavity and pharynx (C00-C14); digestive organs (C15-C26); respiratory organs (C30-C39); breast (C50); female genital organs (C51-C58); male genital organs (C60-C63); cancer from lymphoid tissue (C81-C96). We considered the first cancer event as the incident case if participants were diagnosed with more than one cancer after inception of the study.
Statistical analyses
Baseline characteristics of participants with and without CKD were compared using t-tests, chi-squared tests and analysis of variance.
Cause-specific analysis
Univariate Cox proportional hazard regression analysis was performed to assess the risk factors for cancer in the cohort. All explanatory variables that had an association with cancer at P < 0.25 in the unadjusted analyses were included in the multivariate Cox regression model, performed with a significance level (α = 0.05). Hazard ratios (HR) and the 95% confidence interval (CI) of cancer with reduced kidney function was then compared to those with normal kidney function, after controlling for the effects of age, region of origin, gender, treatment allocation, and BMI. In all models, we adjusted for the effects of smoking status, on the basis of prior knowledge that cigarette smoking increases the risk of cancer [18] [19] [20] . eGFR was measured as a continuous and categorical variable (with CKD defined as eGFR < 60 mL/min/1.73 m 2 ). We checked for any deviations from linearity in the eGFR using linear spline models and other continuous variables, such as age, systolic and diastolic blood pressures, serum blood cholesterol, albuminuria and HbA1c levels, by categorizing each of these variables into quartiles and plotting the estimated regression coefficients against the midpoints of each of the groups. Effect modification was tested between the study factor (eGFR) and all other covariates using two-way interaction terms. The proportional hazards assumptions of all Cox models was assessed by fitting log(time)-dependent covariates in the multivariate models and checking graphically by plotting the Schoenfeld residuals. Site-specific analyses were performed to assess the relationship between reduced kidney function and risk for the six most common cancers within the study cohort.
Competing risk analyses
As a secondary analysis, we conducted a nonparametric estimation of the cumulative incidence of cancer in the diabetic CKD and non-CKD populations, taking into account the informative nature of censoring due to competing risk. The cumulative incidence of cancer is estimated using two main steps. We first considered the event of interest (i.e. cancer incidence) and other competing events (such as cardiovascular-related death) as 'events' and then calculated the Kaplan-Meier estimate of the overall 'events'. Anyone who was not experiencing the 'event' (i.e. event free) was considered censored [21] .
Statistical analyses were performed using SAS version 9.2 (SAS Institute, Cary, NC) and R version 2.11.1.
Sensitivity analyses
To assess the robustness of our results, in sensitivity analyses, reduced kidney function was estimated and defined using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation [22, 23] .
Results
Characteristics of participants
There were a total of 11 140 participants in the study. Forty-four participants (0.4%) were excluded from the analyses due to incomplete serum creatinine profile and an additional 21 (0.2%) participants were excluded because of extreme eGFR values (eGFR >200 mL/min/ 1.73 m 2 ) calculated using the MDRD equation. Baseline characteristics of the study participants with and without CKD are shown in Table 1 . People with CKD were older, . Of those with moderate-stage CKD (defined by an eGFR < 60 mL/min using the MDRD), 2094 (97.5%) had eGFR 30-60 mL/min, 51 (2.4%) had eGFR 15-30 mL/min and 3 (0.1%) had eGFR < 15 mL/min.
Cancer frequency and incidence rate by CKD status Table 2 shows the incidence rate and frequency of common cancers by CKD status. A total of 700 cancers occurred in the cohort within the follow-up period; of these, only 694 were included in the final analyses because of the exclusion of participants with extreme values of eGFR, which were considered abnormal. In patients with CKD, colorectal cancer was the most frequent followed by lung, prostate, urinary tract, breast and skin cancers. In patients without CKD, lung cancer was the most frequently occurring cancer, followed by colorectal, prostate, breast, urinary tract and skin cancers. Prostate and breast cancers were the most common solid organ cancers occurring in men and women, respectively.
After a median follow-up period of 5 years, 7.1% (n = 157) of those with CKD developed cancers compared to 6.1% (n = 543) of those without CKD. The cumulative incidence of cancer by CKD status is shown in Figure 1 . The incidence curves comparing participants with and without CKD appear to slightly separate after ∼3.5 years of follow-up. The cumulative incidence of cancer among those with CKD was 14.7 per 1000 person-years compared to 12.5 per 1000 person-years among those without CKD. Table 3 shows the unadjusted and adjusted HRs for cancer. The unadjusted HR for the overall cancer risk was 1.12 (95% CI: 1.03-1.21, P = 0.01). The adjusted HR for the overall cancer risk was 1.07 (95% CI: 0.89-1.29, P = 0.50) among those with eGFR < 60 mL/min after controlling for the effects of age, gender, current smoking status, region of origin, treatment allocation and BMI.
Effects of CKD on overall cancer risk
Effects of CKD on site-specific cancer risk Figure 2 shows the site-specific risk of the six common cancers by CKD status estimated using the MDRD formula. There was no significant association between reduced kidney function and increased risk of colorectal, breast, lung, prostate, urinary tract and skin cancers after adjusting for the effects of age, gender, BMI, smoking status, treatment allocation and the geographic region from which the patients were recruited.
Sensitivity analyses
We tested the effect of CKD estimated using the CKD-EPI formula and the overall and site-specific risks of cancer. The unadjusted HR for the overall cancer risk was 1.28 (95% CI: 1.08-1.52, P = 0.005) among those with eGFR < 60 mL/min. However, after adjustment, overall cancer risk was not significantly increased (adjusted HR of 0.99, 95% CI: 0.91-1.07, P = 0.75) (Figure 2 ). When site-specific cancers were considered, a borderline significant increase in risk of urinary tract cancers among those with CKD (eGFR < 60 mL/min) compared to those without CKD was observed (adjusted HR of 1.81, 95% CI: 1.02-3.20, P = 0.04), but not of any other cancer types (all P > 0.05). Figure 1 (solid line) shows the cumulative incidence of overall cancer after adjustment for competing events. There were no significant differences in the cumulative incidence of cancer between the CKD and the non-CKD Incidence rate expressed as n (%) of patients. b P-value for differences in the cumulative incidence of cancer between participants with CKD and without CKD (chi-squared test, d.f. = 1). populations after adjusting for the risk of cardiovascular deaths (Gray test: P = 0.109). The unadjusted and adjusted HRs for overall cancer risk were 1.16 (95% CI: 0.968-1.39, P = 0.11) and 1.01 (95% CI: 0.836-1.22, P = 0.91), respectively, among those with eGFR < 60 mL/min taking into account the other causes of death as competing events.
Competing risk analyses
Discussion
Our study suggests that mild to moderate CKD has no effect on overall cancer risk in people with Type 2 diabetes, the commonest cause of end-stage kidney disease in most developed countries. We found that people with diabetes and CKD were no more likely to develop cancer than those without CKD irrespective of how CKD was defined and across all site-specific cancers. The lack of effects was consistent across all models examined. We have shown that the joint effects of diabetes and CKD do not further increase the overall and site-specific risk of cancer compared to having diabetes or CKD alone. Our findings are contrary to some other epidemiological cohorts of CKD and might in part be explained by the presence of similar mechanisms leading to cancer development in patients with CKD or diabetes, such that having CKD and diabetes does not further increase an individual's risk of cancer, in the way it might have done if the mechanisms had been different and additive. Inflammation and chronic infections have long been recognized as risk factors for cancer [24] [25] [26] . CKD and diabetes are both characterized by a state of chronic inflammation [27] [28] [29] . The presence of chronic inflammation, leading to DNA mutation in proliferating cells, and the deregulatory release of oncogenic cytokines and chemokines is thought to be the critical element for cancer development and progression [30] . In patients with Type 2 diabetes, the effects of hyperinsulinemia and the stimulation of insulin-like growth factors have also been considered as the major link to cancer [31] . High levels of insulin stimulate normal cell growth, favoring initiation and the mitogenic potential of pro-oncogenic cells, leading to the observed association between diabetes and various cancer types [32] [33] [34] . Furthermore, it is likely that the oncogenic risk factors such as hyperinsulinemia, obesity, oxidative stress, fibrinolytic and inflammatory abnormalities that are common to both diabetes and CKD [35] [36] [37] , may contribute to the association with cancer in both diabetes and CKD, but without additive effects.
Although an overall increased risk of cancer is not observed in this diabetic CKD cohort, the borderline significant association between urinary tract cancers in the diabetic CKD population compared to those having diabetes alone is an interesting finding. The excess increased risk observed in the sensitivity analyses may be attributed to the independent effects of kidney disease. There is now evidence showing a direct association between urinary tract cancers and people with reduced kidney function, and the pattern is consistent across the full spectrum of CKD [14, 38] . The exact biological rationale for the increased risk is unclear, but it is possible that the potential exposure factors that have caused the renal impairment may also be carcinogenic. Observational studies have produced conflicting findings regarding the risk of cancer in patients with diabetes and in patients with mild to moderately reduced kidney function. This may be a result of confounding, selective and ascertainment biases. Some have shown a positive association between diabetes and solid organ cancers such as breast, colon, lung and endometrial cancers, as well as hematological cancer [8] [9] [10] , while other studies have reported no increase or reduced risk of cancer in patients with diabetes [39, 40] . A meta-analysis of observational studies has found a significantly reduced risk of prostate cancer in diabetic men [41] . Similarly, controversies also exist in the current epidemiological evidence surrounding the risk of cancer in those with early-to moderate-stage CKD. A recent population-based cohort study has reported an excess risk of cancer in subjects with moderatestage CKD, but the association was limited to older men [14] . In contrast, another study of a larger and younger population cohort found a 20% increase in the overall risk of cancer with each SD increase in albuminuria [15] . In addition, an excess risk of Kaposi sarcomas, non-Hodgkin lymphoma, thyroid cancer and cancers of the oral cavity has been reported among those with moderate-to advanced-stage CKD [13] .
Previous studies have reported contradictory findings regarding the effects of angiotensin-converting enzymes inhibitors (ACEI) and the risk of cancers in the diabetic and non-diabetic populations. A cross-sectional study of Type 2 diabetic patients (n = 1003) suggested that ACEI may be protective of cancers of the gastrointestinal tracts [38] but a recent retrospective analysis of breast cancer survivors reported that women on ACEI had at least a 50% increased risk of cancer recurrence compared to those not on ACEI [42] . Contrary to these published results, our univariate and multivariate analyses did not show any possible link between cancer risk and those assigned to intensive blood pressure control using the fixed combination of perindopril/indapamide and are consistent with findings of recent meta-analyses of observational studies indicating the lack of association between ACEI and overall cancer risk [43, 44] .
Despite adjustment for competing events in the competing risk models, we found that it did not alter the results in the primary analyses. Patients with Type 2 diabetes and CKD are at risk of developing cardiovascular disease and are likely to experience the 'competing' risk of dying from other causes and complications of CKD and diabetes, and therefore be less likely to present with cancer outcomes. The lack of association between kidney disease and the overall cancer risk is not limited to the diabetic early-to moderate-stage CKD population but is also Fig. 2 . Adjusted site-specific cancer risk among those with CKD (CKD defined as eGFR < 60 ml/min/1.73 m 2 using the MDRD and the CKD-EPI formulae). evident in the diabetic kidney transplant population [45] . In contrast to the non-diabetic kidney transplant population, comprehensive analyses using data from population-based registries have reported a reduced overall cancer risk among diabetic kidney transplant recipients [46] [47] [48] .
Our study has a number of strengths. It is based on a large and well-characterized cohort drawn from a randomized trial, sourced from over 215 countries, with < 0.6% missing data, < 0.1% loss to follow-up, and a follow-up time of over 56 814 person-years. An almost complete data set of all confounders was also available for analysis. Reporting of new cancer events within the follow-up time of the randomized controlled trial was mandatory and the data were collected using validated data collection forms. Our analyses were also robust, as demonstrated by the consistent findings in the sensitivity analyses. We obtained similar findings of summary estimates when the eGFRs are calculated using the four-variable MDRD and the CKD-EPI equations.
Our study also has a number of potential limitations. The lack of an observed association between overall cancer risk and these two chronic diseases may be due to the limited number of patients with Stages IV and V CKD within the study cohort, and therefore insufficient power to detect any significant differences in cancer risk between people with more advanced-stage CKD and those without CKD. Future studies may consider using pooled analyses from individual patient level data from trials and/or cohort studies to evaluate the risk of cancer in the CKD and the diabetic populations. Secondly, it was not designed specifically to assess cancer outcomes so that cancer events were not routinely confirmed by pathology reports or validated against cancer registry data. Thirdly, the lack of significant effects may also be explained by the relatively short follow-up time of our study, inherent in the conduct of randomized clinical trials. Therefore, despite adjustment for all confounding variables and initial treatment allocation to intensive blood glucose and blood pressure control, there may be residual confounding by other unmeasured factors, which may have altered the strength and the extent of the association between cancer and CKD in this cohort with Type 2 diabetes.
Conclusions
In conclusion, mild-to moderate-stage CKD had no effect on the risk of overall and site-specific cancer in patients with Type 2 diabetes. While diabetes and CKD are both known to be associated with an increased risk of cancer, our findings do not support the notion that CKD augments the risk of cancer in patients with Type 2 diabetes.
